association

Full identifier: http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#association

Assigned to 1 class:

Minted in Nanopublication

 RAsqd9h62v comment approve/disapprove edit as derived nanopublication create new with same template

This is the identifier for this whole nanopublication. http://purl.org/np/RAsqd9h62v... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-06-12T12:28:30.662+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAsqd9h62v... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAsqd9h62v... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAsqd9h62v... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T10:28:30.662Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
venclexta is a bcl 2 inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll 1 1 in combination with azacitidine or decitabine or low dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia aml in adults who are age 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy 1 2 venclexta is indicated for the treatment of adult patients with chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll venclexta is indicated in combination with azacitidine or decitabine or low dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia aml in adults who are age 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy this indication is approved under accelerated approval based on response rates see clinical studies 14 2
Leoni Bücken
2021-06-12T10:28:30.662Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T10:28:30.662Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T10:28:30.662Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T10:28:30.662Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T10:28:30.662Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T10:28:30.662Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T10:28:30.662Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)